Update Alert 8: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
- Resource Type
- journal article
- Authors
- Mackey, Katherine; Kansagara, Devan; Vela, Kathryn
- Source
- Annals of Internal Medicine. 6/15/2021, Vol. 174 Issue 6, pW54-W55. 2p.
- Subject
- *ACE inhibitors
*ANGIOTENSIN-receptor blockers
*SARS-CoV-2
*COVID-19
*INFECTION
- Language
- ISSN
- 0003-4819
In update alert 7, we summarized the state of the evidence for the key questions of this systematic review: whether angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) increase the risk for SARS-CoV-2 infection or worse outcomes and whether these medications are effective in the treatment of COVID-19 ([1]). Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. [Extracted from the article]